Page 151 - Read Online

Page 6 of 6 Cellina et al. Neuroimmunol Neuroinflammation 2018;5:22 I http://dx.doi.org/10.20517/2347-8659.2018.15

37. Onaivi ES. Cannabinoid receptors in brain: pharmacogenetics, neuropharmacology, neurotoxicology, and potential therapeutic
applications. Int Rev Neurobiol 2009;88:335-69.
38. Eljaschewitsch E, Witting A, Mawrin C, Lee T, Schmidt PM, Wolf S, Hoertnagl H, Raine CS, Schneider-Stock R, Nitsch R, Ullrich O.
The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron
2006;49:67-79.
39. Horti AG, Gao Y, Ravert HT, Finley P, Valentine H, Wong DF, Endres CJ, Savonenko AV, Dannals RF. Synthesis and biodistribution of
[11C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2). Bioorg Med Chem 2010;18:5202-7.
40. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 2004;63:901-10.
41. Uddin MJ, Crews BC, Ghebreselasie K, Huda I, Kingsley PJ, Ansari MS, Tantawy MN, Reese J, Marnett LJ. Fluorinated COX-2
inhibitors as agents in PET imaging of inflammation and cancer. Cancer Prev Res 2011;4:1536-45.
42. Giovannini MG, Scali C, Prosperi C, Bellucci A, Pepeu G, Casamenti F. Experimental brain inflammation and neurodegeneration as
model of Alzheimer’s disease: protective effects of selective COX-2 inhibitors. Int J Immunopathol Pharmacol 2003;16:31-40.
43. Aïd S, Bosetti F. Targeting cyclooxygenases-1 and -2 in neuroinflammation: therapeutic implications. Biochimie 2011;93:46-51.
44. Shukuri M, Mawatari A, Ohno M, Suzuki M, Doi H, Watanabe Y, Onoe H. Detection of cyclooxygenase-1 in activated microglia during
amyloid plaque progression: PET studies in Alzheimer’s disease model mice. J Nucl Med 2016;57:291-6.